Cargando…

Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine

Primary liver cancer is the seventh-most-common cancer worldwide and the fourth-leading cause of cancer mortality. In the current era of precision medicine, the diagnosis and management of liver cancer are full of challenges and prospects. Mesoporous nanoparticles are often designed as specific carr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Han, Wang, Ming-Da, Zhu, Jia-Qi, Li, Zhen-Li, Wang, Wan-Yin, Gu, Li-Hui, Shen, Feng, Yang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500788/
https://www.ncbi.nlm.nih.gov/pubmed/36145508
http://dx.doi.org/10.3390/pharmaceutics14091760
_version_ 1784795308570443776
author Wu, Han
Wang, Ming-Da
Zhu, Jia-Qi
Li, Zhen-Li
Wang, Wan-Yin
Gu, Li-Hui
Shen, Feng
Yang, Tian
author_facet Wu, Han
Wang, Ming-Da
Zhu, Jia-Qi
Li, Zhen-Li
Wang, Wan-Yin
Gu, Li-Hui
Shen, Feng
Yang, Tian
author_sort Wu, Han
collection PubMed
description Primary liver cancer is the seventh-most-common cancer worldwide and the fourth-leading cause of cancer mortality. In the current era of precision medicine, the diagnosis and management of liver cancer are full of challenges and prospects. Mesoporous nanoparticles are often designed as specific carriers of drugs and imaging agents because of their special morphology and physical and chemical properties. In recent years, the design of the elemental composition and morphology of mesoporous nanoparticles have greatly improved their drug-loading efficiency, biocompatibility and biodegradability. Especially in the field of primary liver cancer, mesoporous nanoparticles have been modified as highly tumor-specific imaging contrast agents and targeting therapeutic medicine. Various generations of complexes and structures have been determined for the complicated clinical management requirements. In this review, we summarize these advanced mesoporous designs in the different diagnostic and therapeutic fields of liver cancer and discuss the relevant advantages and disadvantages of transforming applications. By comparing the material properties, drug-delivery characteristics and application methods of different kinds of mesoporous materials in liver cancer, we try to help determine the most suitable drug carriers and information media for future clinical trials. We hope to improve the fabrication of biomedical mesoporous nanoparticles and provide direct evidence for specific cancer management.
format Online
Article
Text
id pubmed-9500788
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95007882022-09-24 Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine Wu, Han Wang, Ming-Da Zhu, Jia-Qi Li, Zhen-Li Wang, Wan-Yin Gu, Li-Hui Shen, Feng Yang, Tian Pharmaceutics Review Primary liver cancer is the seventh-most-common cancer worldwide and the fourth-leading cause of cancer mortality. In the current era of precision medicine, the diagnosis and management of liver cancer are full of challenges and prospects. Mesoporous nanoparticles are often designed as specific carriers of drugs and imaging agents because of their special morphology and physical and chemical properties. In recent years, the design of the elemental composition and morphology of mesoporous nanoparticles have greatly improved their drug-loading efficiency, biocompatibility and biodegradability. Especially in the field of primary liver cancer, mesoporous nanoparticles have been modified as highly tumor-specific imaging contrast agents and targeting therapeutic medicine. Various generations of complexes and structures have been determined for the complicated clinical management requirements. In this review, we summarize these advanced mesoporous designs in the different diagnostic and therapeutic fields of liver cancer and discuss the relevant advantages and disadvantages of transforming applications. By comparing the material properties, drug-delivery characteristics and application methods of different kinds of mesoporous materials in liver cancer, we try to help determine the most suitable drug carriers and information media for future clinical trials. We hope to improve the fabrication of biomedical mesoporous nanoparticles and provide direct evidence for specific cancer management. MDPI 2022-08-23 /pmc/articles/PMC9500788/ /pubmed/36145508 http://dx.doi.org/10.3390/pharmaceutics14091760 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wu, Han
Wang, Ming-Da
Zhu, Jia-Qi
Li, Zhen-Li
Wang, Wan-Yin
Gu, Li-Hui
Shen, Feng
Yang, Tian
Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine
title Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine
title_full Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine
title_fullStr Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine
title_full_unstemmed Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine
title_short Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine
title_sort mesoporous nanoparticles for diagnosis and treatment of liver cancer in the era of precise medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500788/
https://www.ncbi.nlm.nih.gov/pubmed/36145508
http://dx.doi.org/10.3390/pharmaceutics14091760
work_keys_str_mv AT wuhan mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine
AT wangmingda mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine
AT zhujiaqi mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine
AT lizhenli mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine
AT wangwanyin mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine
AT gulihui mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine
AT shenfeng mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine
AT yangtian mesoporousnanoparticlesfordiagnosisandtreatmentoflivercancerintheeraofprecisemedicine